TD Cowen analyst Joseph Thome has maintained their bullish stance on NTLA stock, giving a Buy rating on November 4.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Joseph Thome has given his Buy rating due to a combination of factors surrounding Intellia Therapeutics. Despite the recent setback in the ATTR program, where a patient death led to a pause in the study, Thome sees potential in the company’s ongoing efforts. The management has expressed confidence in the HAE program, which remains unaffected by the recent safety concerns and is progressing towards its Phase III data release by mid-2026.
Thome acknowledges the challenges faced by Intellia, particularly the need for stringent safety measures in light of the recent events. However, he is optimistic about the promising early data from the HAE program, especially regarding long-term attack rate freedom. This optimism, shared by key opinion leaders, supports his Buy rating as the company shifts its focus to the HAE program, which could lead to significant advancements and potential regulatory approval in the coming years.
In another report released on November 4, JonesTrading also maintained a Buy rating on the stock with a $25.00 price target.
Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is neutral on the stock.